The recent surge in funding into niche pharmaceutical companies, particularly those focusing スロット on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and impressive returns is clear, the linked risks are also significan